Visit the Website for Patients 
Français
Subscribe to our newsletter!
Follow the latest news from CATALIS and Clinical Trials Quebec
Approval Performances
1501-001
Advanced Solid Tumours Phase I
- 7.1 weeks
- 1st site activated worldwide and Canadian FPI
ProHer
Breast Cancer Phase IIIb
- 10.6 weeks
- 1st site activated worldwide
ProHer
Breast Cancer Phase IIIb
- 25 weeks
TCD 17240
Advanced Solid Tumours Phase I/II
- 16.1 weeks
- Canadian regulatory delay 1st site activated worldwide and Canadian FPI
VICTORION-2
Cardiology Phase III
- 7.7 weeks
- 1st site activated worldwide
VICTORION-2
Cardiology Phase III
- 8 weeks
- 2nd site activated worldwide
VICTORION-2
Cardiology Phase III
- 8.7 weeks
- 3rd site activated worldwide and FPI globally
VICTORION-2
Cardiology Phase III
- 9.9 weeks
- 5th site activated worldwide
20210181 (MARITIME-1)
Obesity Phase III
- 6.4 weeks
20210181 (MARITIME-1)
Obesity Phase III
- 8.2 weeks
20230005
Prostate Cancer Phase III
- 13.4 weeks
- 1st site activated in Canada and Canadian FPI
20240031
Oncology Phase I
- 9.4 weeks
22143
Prostate Cancer Phase I
- 9.4 weeks
- 1st site activated in Canada
22143
Prostate Cancer Phase I
- 13.4 weeks
- 2nd site activated in Canada
22143
Prostate Cancer Phase I
- 13.4 weeks
- 3rd site activated in Canada
221611 (Crown)
HIV Phase IIIb
- 8.6 weeks
- 1st site activated in Canada
223050
Prostate Cancer Phase I/II
- 8.6 weeks
- 1st site activated in Canada
223050
Prostate Cancer Phase I/II
- 11.8 weeks
- 2nd site activated in Canada
223559
Advanced Solid Tumors Phase I/II
- 13.8 weeks
- Canadian FPI
223559
Advanced Solid Tumors Phase I/II
- 14 weeks
223674 (B7H3)
Oncology (Lung Cancer) Phase III
- 8 weeks